Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

Our proprietary delivery system allows a class of existing high potency oncology drugs to be dosed orally to improve patient outcomes and quality of life.

Our Src Kinase Inhibitors also bind to a novel site on tubulin heterodimers thereby broadening their anti-tumor activity beyond that provided by Src inhibition alone.

Transformative, oncology-focused and highly synergistic pipeline with late stage product candidates.

Athenex IPO on the NASDAQ Stock Market, June 14, 2017

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.   Learn More

Photography by Christopher Galluzzo / Nasdaq, Inc.
Photography by Christopher Galluzzo / Nasdaq, Inc.

Oraxol

Oraxol (Oral Paclitaxel) is an oral formulation of Paclitaxel developed by Athenex that is administered with a second drug (HM30181A) to promote absorption of paclitaxel in the gastrointestinal tract.  The World Health Organization has designated Paclitaxel as a critical anti-cancer drug,.  We believe an oral form of paclitaxel will be a major advance in the treatment of cancer, and are rapidly advancing our lead Orascovery drug candidate, Oraxol. In 2015, we started enrolling patients in a Phase 3 Oraxol study in a head to head comparison with the standard IV formulation of paclitaxel.  The first interim analysis from this Phase 3 study in metastatic breast cancer is expected in 2017.  In October 2016, we entered into a clinical study collaboration with Eli Lilly and Company to evaluate Oraxol in combination with Lilly’s approved monoclonal antibody Cyramza (ramucirumab) to treat gastric, gastric- esophageal and esophageal cancer.  The ability to dose paclitaxel orally is expected to   provide flexibility in the design and optimization of combination regimens, resulting in further advances in the treatment of cancer.

Learn More

Important Information

Click Here for Important information for Health Care Providers regarding Sodium Bicarbonate Injection

Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program

October 05, 2017

BUFFALO, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that a planned interim analysis of the Oraxol 001 Phase III Clinical Trial has been conducted and reviewed by an independent Drug Safety Monitoring Board (DSMB). The DSMB unanimously recommended continuation of the study. The DSMB was impressed by the conduct of the study in achieving a good overall response rate. The DSMB was reassured by the expected difference in safety profile between Oraxol and IV paclitaxel. In particular, the adverse event of painful neuropathy was uncommon with Oraxol treatment. The DSMB encouraged the rapid patient recruitment toward the scheduled second interim analysis at 180 patients.

Read more

Governor Cuomo Announces Major Expansion of Athenex — Creating 1,400 Jobs in Western New York

Athenex (formerly Kinex) to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo over the next ten years.

State investing $225 million to support the Buffalo Medical Innovation and Commercialization Hub and help create new opportunities for the region.

Governor Andrew M. Cuomo recently announced a major expansion of Athenex that will create 1,400 jobs throughout Western New York. This announcement, made possible by a partnership with the SUNY Polytechnic Institute, includes a major expansion of Athenex’s North American headquarters at the Conventus Building in Buffalo, as well as the creation of a state-of-the-art, 300,000 square foot manufacturing facility in Dunkirk.

Read more

Rendering of new 300,000 square foot facility
Rendering of new 300,000 square foot facility

Athenex Completes Public/Private Partnership Agreement with Chongqing, China To Construct Two New Pharmaceutical Manufacturing Plants

Athenex recently announced the completion and execution of a definitive agreement with the Banan District in Chongqing, China to construct two separate pharmaceutical manufacturing plants on Banan sites already identified and selected by Athenex management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications, and Athenex will equip the facilities.

Read more